APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Endothelial Growth Factor (VEGF) Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025199 pages

Choose your research edition.

Industry ResearchVascular Endothelial Growth Factor (VEGF) Antibodies Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vascular Endothelial Growth Factor (VEGF) Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vascular Endothelial Growth Factor (VEGF) Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vascular Endothelial Growth Factor (VEGF) Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vascular Endothelial Growth Factor (VEGF) Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vascular Endothelial Growth Factor (VEGF) Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Company

Sanofi

Novartis

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Regeneron

Bristol-Myer Squibb

Boehringer Ingelheim

Abcam Plc

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Type

Aflibercept

Bevacizumab

Ranibizumab

Others

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Cancer Research Institutes

Others

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor (VEGF) Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor (VEGF) Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor (VEGF) Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vascular Endothelial Growth Factor (VEGF) Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vascular Endothelial Growth Factor (VEGF) Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vascular Endothelial Growth Factor (VEGF) Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends Table 2. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Drivers Table 3. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Opportunities and Challenges Table 4. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Restraints Table 5. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Manufacturers Table 9. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers, Product Type & Application Table 13. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vascular Endothelial Growth Factor (VEGF) Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aflibercept Table 17. Major Manufacturers of Bevacizumab Table 18. Major Manufacturers of Ranibizumab Table 19. Major Manufacturers of Others Table 20. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2026) & (W Units) Table 22. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2027-2032) & (W Units) Table 23. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2026) Table 24. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2027-2032) Table 25. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021-2026) & (W Units) Table 27. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2027-2032) & (W Units) Table 28. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2026) Table 29. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Specialty Clinics Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Ambulatory Surgical Centers Table 33. Major Manufacturers of Cancer Research Institutes Table 34. Major Manufacturers of Others Table 35. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2026) & (W Units) Table 37. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2027-2032) & (W Units) Table 38. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2026) Table 39. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2027-2032) Table 40. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021-2026) & (W Units) Table 42. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2027-2032) & (W Units) Table 43. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2026) Table 44. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2027-2032) Table 45. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2021-2026) & (W Units) Table 47. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Region (2021-2026) Table 48. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 52. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 53. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 55. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 62. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2021-2026) Table 66. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2027-2032) Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 71. Sanofi Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 76. Novartis Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 81. Merck Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 86. Roche Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 96. Pfizer Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. Bayer Company Information Table 103. Bayer Business Overview Table 104. Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 106. Bayer Recent Development Table 107. AstraZeneca Company Information Table 108. AstraZeneca Business Overview Table 109. AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 111. AstraZeneca Recent Development Table 112. Regeneron Company Information Table 113. Regeneron Business Overview Table 114. Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 116. Regeneron Recent Development Table 117. Bristol-Myer Squibb Company Information Table 118. Bristol-Myer Squibb Business Overview Table 119. Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 121. Bristol-Myer Squibb Recent Development Table 122. Boehringer Ingelheim Company Information Table 123. Boehringer Ingelheim Business Overview Table 124. Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 126. Boehringer Ingelheim Recent Development Table 127. Abcam Plc Company Information Table 128. Abcam Plc Business Overview Table 129. Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 131. Abcam Plc Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors List Table 135. Vascular Endothelial Growth Factor (VEGF) Antibodies Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Vascular Endothelial Growth Factor (VEGF) Antibodies Product Image Figure 2. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (2021-2032) & (W Units) Figure 5. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vascular Endothelial Growth Factor (VEGF) Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aflibercept Image Figure 9. Bevacizumab Image Figure 10. Ranibizumab Image Figure 11. Others Image Figure 12. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2032) Figure 15. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2032) Figure 18. Specialty Clinics Image Figure 19. Hospitals Image Figure 20. Ambulatory Surgical Centers Image Figure 21. Cancer Research Institutes Image Figure 22. Others Image Figure 23. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2032) Figure 26. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2032) Figure 29. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 31. U.S. Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 36. Germany Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 43. China Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 51. Brazil Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Vascular Endothelial Growth Factor (VEGF) Antibodies Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032) & (US$ Million) Figure 62. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032) & (US$ Million) Figure 64. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Vascular Endothelial Growth Factor (VEGF) Antibodies Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Vascular Endothelial Growth Factor (VEGF) Antibodies Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Aflibercept
  • Bevacizumab
  • Ranibizumab
  • Others
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Regeneron
  • Bristol-Myer Squibb
  • Boehringer Ingelheim
  • Abcam Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Dynamics
  1. 2.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends
  2. 2.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Drivers
  3. 2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Opportunities and Challenges
  4. 2.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Restraints
3 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Manufacturers
  1. 3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vascular Endothelial Growth Factor (VEGF) Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vascular Endothelial Growth Factor (VEGF) Antibodies Tier 1, Tier 2, and Tier 3
4 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Type
  1. 4.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Type Introduction
  2. 4.1.1 Aflibercept
  3. 4.1.2 Bevacizumab
  4. 4.1.3 Ranibizumab
  5. 4.1.4 Others
  6. 4.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type
  7. 4.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2032)
  9. 4.2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2032)
  10. 4.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type
  11. 4.3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021-2032)
  13. 4.3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2032)
5 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Application
  1. 5.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Cancer Research Institutes
  6. 5.1.5 Others
  7. 5.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application
  8. 5.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2032)
  10. 5.2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2032)
  11. 5.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application
  12. 5.3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021-2032)
  14. 5.3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2032)
6 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region
  1. 6.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region
  1. 7.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region
  2. 7.1.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032)
  8. 7.2.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Regeneron
  56. 8.10.1 Regeneron Company Information
  57. 8.10.2 Regeneron Business Overview
  58. 8.10.3 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  60. 8.10.5 Regeneron Recent Developments
  61. 8.11 Bristol-Myer Squibb
  62. 8.11.1 Bristol-Myer Squibb Company Information
  63. 8.11.2 Bristol-Myer Squibb Business Overview
  64. 8.11.3 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  66. 8.11.5 Bristol-Myer Squibb Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Abcam Plc
  74. 8.13.1 Abcam Plc Company Information
  75. 8.13.2 Abcam Plc Business Overview
  76. 8.13.3 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  78. 8.13.5 Abcam Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Value Chain Analysis
  2. 9.1.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Production Mode & Process
  6. 9.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors
  9. 9.2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst